TG003 is primarily utilized in research settings to study and modulate pre-mRNA splicing processes. It acts as a selective inhibitor of CLK (CDC-like kinase) family proteins, which are involved in the regulation of splicing factors. By inhibiting these kinases, TG003 allows researchers to investigate the role of alternative splicing in various biological contexts, including gene expression regulation and disease mechanisms. This compound is particularly valuable in studies related to cancer, neurodegenerative diseases, and other conditions where splicing dysregulation plays a critical role. Additionally, TG003 serves as a tool to explore potential therapeutic strategies targeting splicing machinery. Its application extends to drug discovery efforts aimed at developing novel treatments for splicing-related disorders.